---
title: "Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295525278.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-08-11T08:49:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295525278.md)
  - [en](https://longbridge.com/en/news/295525278.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295525278.md)
generator: "portal-rs"
---

# Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [JAZZ.US](https://longbridge.com/en/quote/JAZZ.US.md)

## Related News & Research

- [JAZZ: Strong commercial execution and pipeline innovation drive robust growth and future potential](https://longbridge.com/en/news/298495735.md)
- [JAZZ: Record growth, new launches, and AI-driven strategies fuel rare disease expansion and raised outlook](https://longbridge.com/en/news/298625568.md)
- [Jazz Pharma CEO Renee D. Gala disposes of ordinary shares worth $970,664.07](https://longbridge.com/en/news/298641896.md)
- [Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera](https://longbridge.com/en/news/297431759.md)
- [MBX Biosciences appoints Jeff Held chief legal officer](https://longbridge.com/en/news/298315788.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**